Dr. Barry Schechter MD
Director of Corneal and External Diseases, FLORIDA EYE MICROSURGICAL INSTITUTE INC
Member of the Healthcare Council
Council Member Biography
Barry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal, refractive, and cataract surgery, and glaucoma. He has reviewed articles for Cornea, British Journal of Ophthalmology, and Journal of the American Academy of Ophthalmology. Dr. Schechter has lectured internationally and published about treatment of ocular tumors , on lens implants, on dry eyes, and written a textbook chapter on surgical techniques. He is involved in clinical research and consults for several ophthalmic pharmaceutical companies. (This is me - Update Profile)
Employment History
- 2005 - Unspecified
- Director of Corneal and External Diseases, FLORIDA EYE MICROSURGICAL INSTITUTE INC
GLG NewsSM Analyses by Barry Schechter(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Bausch makes foray into presbyopic arena
January 29, 2008
Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
-
Newly identified risks for refractive surgery
April 16, 2007
Researchers report 13 cases of MRSA keratitis after laser refractive surgery | www.osnsupersite.com
Refractive surgery is taken for granted by patients to "get rid of their glasses and contact lenses". They rarely consider the possibility of loss of vision.
-
ISTA takes the lead in topical NSAID therapy
February 14, 2007
ISTA Pharmaceuticals Announces Positive Preliminary Xibrom Once-daily Formulation Clinical Results From U.S. Phase III Trials | pharmalive.com
There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.
Compliance with all medications is always an issue, and the use of a once daily medication potentially makes this a non-issue. I have been impressed with the BID Xibrom and my patients in the phase 3 trial did exceptionally well.
I expect that this will be well received, pending acceptance of formularies. -
Additional Thoughts on Fusarium
May 10, 2006
Doubt Cast on Early Theory on Eye Infections | www.nytimes.com
Multiple species of Fusarium have been reported as pathogens.
-
ReStor gradually becoming more popular
May 10, 2006
Alcon Still Not Living Up to Valuation | www.fool.com
Dr Packer writes that the ReStor lens is taking time to catch on with cataract surgeons.
Leading institutions connect with Barry Schechter through GLG
GLG Study Groups with Barry Schechter(?)
| Study Group Name | No. Members |
|---|---|
| Ophthalmologists | 1610 |
| Ophthalmologists (US) | 1133 |
| Infectious Diseases Physicians (US) | 885 |
| Corneal and Refractive Ophthalmic Surgeons (US) | 518 |
| Refractive Surgeons (US) | 309 |
GLG Live Meetings with Barry Schechter(?)
Barry Schechter has not participated in any GLG Live Meetings.